Page 9 - Lupin

Lupin Ltd receives USFDA approval for smoking cessation drug Chantix

The product will be manufactured at Lupin's Pithampur facility in India, the company said in a regulatory filing

Lupin announces launch of world's first FDC drug for chronic lung disease

Lupin Vilfuro-G is the only FDC that uniquely combines Vilanterol, Fluticasone Furoate, and Glycopyrronium Bromide for the long-term management and treatment of moderate to severe COPD

Lupin ties up with Amman Pharma for commercialisation of biosimilar product

Drug firm Lupin on Friday said it has tied up with Amman Pharma to market a biosimilar product in the Middle East region. The company has inked a licensing pact for the commercialisation and marketing of Ranibizumab, a biosimilar of Lucentis, in various countries including Saudi Arabia, UAE, Iraq and Lebanon. Ranibizumab is indicated for the treatment of patients with neovascular age-related macular degeneration, macular edema following retinal vein occlusion (RVO) and diabetic macular edema, among others. Shares of the company on Friday ended 2.04 per cent down at Rs 1,180.20 apiece on the BSE.

Lupin, Amman Pharma collaborates for exclusive marketing of Ranibizumab

Lupin Limited has partnered with pharmaceutical manufacturer Amman Pharmaceuticals Industries for exclusive marketing and commercialisation of Ranibizumab in the West Asian region

Lupin's net profit jumps nearly four-fold on strong US growth, stock up

US sales cross $200 million for the first time in two years, beat analyst expectations

Stocks to Watch: Vedanta, Adani Ports, Lupin, Tata Power, MCX, BHEL, IFCI

Stocks to watch on Thursday, November 09, 2023: Adani Ports Sri Lankan JV to get $553 mn funding from the US DFC. Patanjali, Phoenix Mills and Brigade Enterprises to react to strong jump in Q2 profit.

Lupin introduces generic version of Zemuron Injection in United States

The newly introduced Rocuronium Bromide Injection is available in two formulations

Lupin receives approval from the US FDA for its Selexipag for injection

In 2022, sales of the Selexipag Franchise in the US stood at $ 1.1 billion. The sales for January 1 to September 30, 2023, stood at $978 million

Stocks to Watch today: Axis Bank, Tech M, Vedanta, Delta Corp, ONGC, NDTV

Stocks to watch on Wednesday, October 25, 2023: The Bombay High Court has directed the Directorate General of GST Intelligence, Hyderabad, to not pass a final orders against Delta Corp

Lupin receives tentative approval from US FDA for apalutamide tablets

Lupin develops and commercialises a wide range of branded and generic formulations, biotechnology products, and Active Pharmaceutical Ingredients (APIs) in over 100 markets

Lupin gets EIR Status from US FDA for Nagpur Unit-1 manufacturing facility

The EIR was issued following the facility's inspection conducted in July 2023

Lupin inks pact to acquire five legacy brands from Menarini Group

Lupin has secured the rights to five brands - Piclin, Menoctyl, Sucramal O, Pyridium and Distaclor

Lupin acquires five legacy brands from Meranini to solidify its portfolio

Lupin has already been marketing these brands in India since July 2021 under an agreement with A Menarini India Private Limited but will now have the full trademark ownership of the five brands

Stocks to Watch, Sep 12: L&T, RIL, Lupin, Hindalco, TVS Supply, Power Grid

Stocks to watch on Tuesday, September 12, 2023: From L&T raising its share buyback price, Bajaj Finance planning to enter new car loans segment, Power Grid to trade ex-bonus and more.

Lupin to sell generic respiratory drugs on Mark Cuban's online pharmacy

The partnership with Cuban-backed Cost Plus Drugs is expected to bolster Lupin's U.S. business, which already accounts for nearly 33% of its 2023 revenue

J&J, Lupin cut prices for tuberculosis drug in lower-income countries

(Reuters) - Johnson & Johnson and Indian drugmaker Lupin will supply their versions of the tuberculosis drug bedaquiline at a significantly cheaper price in low- and middle-income countries, a global anti-tuberculosis group said on Wednesday.

Stocks to Watch, Aug 30: Zee Ent, Zomato, Suzlon, Lupin, Airtel, Unichem

Stocks to Watch today, August 30, 2023: Billionaire Sunil Mittal's backed telecom services provider Airtel Uganda Ltd plans to raise $216 million in an initial public offering (IPO)

Lupin gets USFDA nod to market generic lung disease treatment capsule

Pharma major Lupin Ltd on Tuesday said it received approval from the US health regulator to market its generic Pirfenidone capsules used for the treatment of lung disease known as idiopathic pulmonary fibrosis. The approval granted by the US Food and Drug Administration (USFDA) is for the abbreviated new drug application for Pirfenidone capsules of 267 mg strength, Lupin said in a regulatory filing. The drug is the generic equivalent of Esbriet Capsules, 267 mg of Hoffmann La Roche Inc. This product will be manufactured at Lupin's Pithampur facility in India, it added. Pirfenidone capsules had estimated annual sales of USD 95 million in the US, Lupin said citing IQVIA MAT June 2023 data.

Lupin receives USFDA approval for generic blood pressure lowering drug

Pharma major Lupin Ltd on Wednesday said it has received approval from the US health regulator to market its generic Metoprolol Succinate extended-release tablets used for lowering blood pressure. The approval by the US Food and Drug Administration (USFDA) for the abbreviated new drug application is for Metoprolol Succinate extended-release tablets of strengths 25 mg, 50 mg, 100 mg, and 200 mg, Lupin said in a regulatory filing. These are generic equivalent of Toprol-XL Tablets of Sequel Therapeutics, LLC. This product will be manufactured at Lupin's Pithampur facility in India, the company said. Metoprolol Succinate extended-release tablets had an estimated annual sales of USD 305 million in the US, the company said citing IQVIA MAT June 2023 data.

Pharma major Lupin gets USFDA approval for its generic antibiotic

Pharma major Lupin Ltd on Monday said it has received approval from the US health regulator to market its generic antibiotic Doxycycline Hyclate delayed-release tablets used to treat bacterial infections. The approval by the US Food and Drug Administration (USFDA) is for the abbreviated new drug application for Doxycycline Hyclate delayed-release tablets of strengths 50 mg, 60 mg, 75 mg, 80 mg, 100 mg, 120 mg, 150 mg, and 200 mg, Lupin said in a regulatory filing. This product will be manufactured at Lupin's Pithampur facility in India, it added. Doxycycline Hyclate Delayed-Release tablets had estimated annual sales of USD 9 million in the US, the company said citing IQVIA MAT June 2023 data.